Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization

SOLENO THERAPEUTICS INC

Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.
Underwriters have 30-day option to purchase up to an additional 352,941 shares at same price.
Proceeds to fund commercialization of VYKAT XR (diazoxide choline) for Prader-Willi syndrome, approved March 26, 2025.
Also funds EU regulatory/market development, R&D, and general corporate purposes.
Offering expected to close July 11, 2025; joint book-runners: Goldman Sachs, Guggenheim, TD Cowen, Cantor, Oppenheimer.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.